Preclinical CRO Services for Age-Related Macular Degeneration (AMD)
Accelerate Your AMD Therapies from Bench to Clinic. Integrated platform featuring validated NaIO₃ & Laser-induced models, advanced retinal imaging (OCT/FFA), and functional ERG readouts.
Advanced Preclinical AMD Models & Customized Research Services
Age-related macular degeneration (AMD) remains a leading cause of irreversible vision loss globally, characterized by the progressive atrophy of retinal pigment epithelial (RPE) cells and subsequent photoreceptor degeneration. To accelerate your drug discovery and therapeutic development, we provide comprehensive mouse models that recapitulate the complex pathology of both dry and wet AMD, including NaIO₃-induced RPE degeneration (dry AMD), laser-induced CNV (wet AMD), and two-stage laser–induced subretinal fibrosis.
Our platform integrates high-resolution structural and functional readouts—including Optical Coherence
Tomography (OCT), fundus imaging, Electroretinogram (ERG), and multi-marker immunofluorescence—to
deliver robust, translational data packages tailored to your specific research goals. From validating
RPE-protective therapies to assessing complement inhibitors, our expert-led services offer the precision
and depth required to advance your ophthalmic pipeline from bench to clinic.
{{ item.title }}
{{static_tabs[0].title}}
Disease-Relevant Induced AMD Models
| Model name | Key Mechanism | Pathology & Clinical Relevance | Action |
|---|---|---|---|
| NaIO₃-Induced Dry AMD Model | Systemic administration of Sodium Iodate (NaIO₃) to selectively induce oxidative stress in RPE cells | Mimics RPE cell death and geographic atrophy. |
|
| Laser-Induced CNV (Wet AMD) Model | Laser photocoagulation applied to the ocular fundus to rupture Bruch's membrane and the RPE | Mimics Neovascular AMD (nAMD), Induces localized choroidal neovascularization (CNV) and vascular leakage. |
|
| Two-Stage Laser-Induced Subretinal Fibrosis Model | Sequential laser insults to trigger localized injury and sustained inflammatory response, promoting fibrous tissue proliferation and scar formation | Mimics Advanced nAMD & PCV Scarring. |
|
Relevant Model
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
；
|
+
|
Next Page
{{static_tabs[1].title}}
Our in vivo pharmacology platform integrates standardized AMD disease modeling with precise
ocular drug delivery to ensure robust, reproducible evaluation of your therapeutic candidates.
Precision Modeling & Drug Delivery
| Model Type | Reference Compound | Route of Administration | Mechanism of Action (MoA) | Key Efficacy Readouts |
|---|---|---|---|---|
| NaIO₃-induced Retinal Degeneration | Pegcetacoplan | Tail Vein Injection | C3 Complement Inhibitor | Validates therapeutic efficacy via preservation of RPE/ONL structural integrity, restoration of visual function (ERG), and downregulation of complement activation markers. |
| Laser-induced CNV | Aflibercept | Intravitreal Injection | Anti-VEGF Agent | Confirms anti-angiogenic potency through significant suppression of vascular leakage (FFA) and regression of neovascular/fibrotic lesion area. |
Modeling & Administration Protocols
Standardized Laser-Induced CNV Protocol
- Laser Wavelength: 532 nm
- Power: 300 mW
- Spot Size: 50 μm
- Duration: 0.1 s
Optimized Ocular Drug Administration
- Intravitreal Injection (IVT):Direct delivery to the vitreous cavity to target neovascularization.
- Systemic Injection (Tail Vein):Systemic administration optimized for consistent RPE oxidative stress induction.
{{static_tabs[2].title}}
We deliver precise efficacy validation tailored to specific AMD models:
| Analysis Category | Specific Services | Key Applications & Targets |
|---|---|---|
| Pathology & Biomarker Analysis | Immunofluorescence (Flat-mount & Section) | Visualize and quantify neovascular lesions (CNV), subretinal fibrosis, and inflammatory cell infiltration using high-specificity immunolabeling. |
| Gene Expression (qPCR) & Apoptosis (TUNEL) | Assess molecular mechanisms via inflammatory/fibrotic gene profiling and quantify RPE/photoreceptor apoptosis for neuroprotection studies. | |
| Pathology & Morphology | Histology (H&E Staining) | Evaluate retinal structural integrity, layer thickness (ONL/INL), and ocular safety through rigorous histopathological morphometry. |
| Physiological & Biochemical Analysis | Physiological & Biochemical Analysis | Monitor longitudinal therapeutic efficacy via non-invasive structural (OCT), vascular leakage (FFA), and functional (ERG) phenotypic analysis. |
Case Studies
{{ item.label }}
{{v2.label}}
{{v2.title}}
{{item.title}}
Why Partner with Cyagen?
Translational Relevance
Models mimicking key pathologies of dry (RPE atrophy) and wet AMD (CNV, fibrosis), validated with standard-of-care drugs (e.g., Aflibercept, Pegcetacoplan).
Advanced Imaging Platform
In-house state-of-the-art equipment including OCT (Micron IV), Flash ERG, and FFA for longitudinal monitoring.
Comprehensive Readouts
From functional endpoints (visual acuity/ERG) to molecular pathology (qPCR for inflammatory/fibrotic markers) and high-quality histology.
Related Resources
Events & Webinars
Life Science Exhibits at UC San Francisco - Mission Bay
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/cKO Mice
View Details
Blogs & Insights
Advancing C5AR1 Drug Development in 2026: How Humanized Mouse Models Support Next-Generation C5AR1 Antagonists
View Details
Resource Valut
Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
